BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Eisai Centre for G2D2 commences operation towards dementia treatment

July 16, 2019 | News

A focused drug discovery approach that integrates human genetics, data science, precision chemistry



Japan based pharmaceutical firm Eisai Co., Ltd. has announced that the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility in Cambridge, Massachusetts, U.S., held its opening ceremony and has begun full-scale research activities.

G2D2 integrates Eisai's strengths cultivated from human genetics, data sciences and precision chemistry for the novel drug discovery approach, and this approach will focus on the immunodementia to expand Eisai's dementia pipeline beyond amyloid-beta (A?) and tau. Specifically, G2D2 will leverage human genetics and human biology to attempt to discover potential innovative medicines for dementia, which target the brain's immune system.

G2D2 is located in Cambridge, Massachusetts, one of the world's leading biotechnology clusters where academic institutions and private research organizations are concentrated, and will collaborate with the world-class science. Taking advantage of the benefits of its location, The Eisai Incubator for NeuroDiscovery (e-IND) will provide space to Cambridge-based start-up/spin-out companies conducting high-risk but potentially transformative research that can impact the discovery of breakthrough neuroscience therapeutics. G2D2 also plans to contribute to the development of next-generation scientific leaders in the Boston and Cambridge areas through internships, training programs and postdoctoral fellowships in genetics and drug discovery science.

With the full-scale operation of G2D2, Eisai is striving to discover innovative dementia treatments using a multi-dimensional, comprehensive approaches to fulfill unmet needs and increase the benefits for patients and their families.